Skip to contentE
Editas Medicine, Inc.
E
EDITEditas Medicine, Inc. Q2 2022 · 10-Q
Revenue$6.36M$6.36M+1,578.6% vs Q2 2021 Net Income-$53.45M-$53.45MN/M vs Q2 2021 EPS Diluted-$0.78-$0.78N/M vs Q2 2021 Operating Income-$54,234,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Editas Medicine, Inc. · CIK 1650664 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$38,477,000N/M Margins · derivedOperating margin-852.5%+13765.2 pt vs Q2 2021
Net margin-840.2%+13739.2 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 3, 2022 · 34 d after period end